Advances and Clinical Outcomes in Hodgkin Lymphoma in the Era of Novel Therapies

被引：0
作者：
Paviglianiti, Annalisa [1 ,2 ]
Rampi, Nicolo [1 ,3 ]
机构：
[1] Inst Catala Oncol Hosp, Clin Hematol Dept, Barcelona 08908, Spain
[2] Inst Invest Biomed Bellvitge IDIBELL, Barcelona 08908, Spain
[3] Univ Milan, Dept Oncol & Hemato Oncol, I-20122 Milan, Italy
来源：
JOURNAL OF CLINICAL MEDICINE | 2023年 / 12卷 / 05期
关键词：
BRENTUXIMAB VEDOTIN; CELL TRANSPLANTATION; PHASE-II;
D O I：
10.3390/jcm12051928
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 14 条
  • [1] Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
    Advani, Ranjana H.
    Moskowitz, Alison J.
    Bartlett, Nancy L.
    Vose, Julie M.
    Ramchandren, Radhakrishnan
    Feldman, Tatyana A.
    LaCasce, Ann S.
    Christian, Beth A.
    Ansell, Stephen M.
    Moskowitz, Craig H.
    Brown, Lisa
    Zhang, Chiyu
    Taft, David
    Ansari, Sahar
    Sacchi, Mariana
    Ho, Linda
    Herrera, Alex F.
    [J]. BLOOD, 2021, 138 (06) : 427 - 438
  • [2] Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma
    Ansell, Stephen M.
    Radford, John
    Connors, Joseph M.
    Dlugosz-Danecka, Monika
    Kim, Won-Seog
    Gallamini, Andrea
    Ramchandren, Radhakrishnan
    Friedberg, Jonathan W.
    Advani, Ranjana
    Hutchings, Martin
    Evens, Andrew M.
    Smolewski, Piotr
    Savage, Kerry J.
    Bartlett, Nancy L.
    Eom, Hyeon-Seok
    Abramson, Jeremy S.
    Dong, Cassie
    Campana, Frank
    Fenton, Keenan
    Puhlmann, Markus
    Straus, David J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (04) : 310 - 320
  • [3] Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
    Armand, Philippe
    Engert, Andreas
    Younes, Anas
    Fanale, Michelle
    Santoro, Armando
    Zinzani, Pier Luigi
    Timmerman, John M.
    Collins, Graham P.
    Ramchandren, Radhakrishnan
    Cohen, Jonathon B.
    De Boer, Jan Paul
    Kuruvilla, John
    Savage, Kerry J.
    Trneny, Marek
    Shipp, Margaret A.
    Kato, Kazunobu
    Sumbul, Anne
    Farsaci, Benedetto
    Ansell, Stephen M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (14) : 1428 - +
  • [4] Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial
    Broeckelmann, Paul J.
    Buehnen, Ina
    Meissner, Julia
    Trautmann-Grill, Karolin
    Herhaus, Peter
    Halbsguth, Teresa V.
    Schaub, Valdete
    Kerkhoff, Andrea
    Mathas, Stephan
    Bormann, Matthias
    Dickhut, Andreas
    Kaul, Helen
    Fuchs, Michael
    Kobe, Carsten
    Baues, Christian
    Borchmann, Peter
    Engert, Andreas
    von Tresckow, Bastian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (06) : 1193 - +
  • [5] Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
    Chen, Robert
    Zinzani, Pier Luigi
    Lee, Hun Ju
    Armand, Philippe
    Johnson, Nathalie A.
    Brice, Pauline
    Radford, John
    Ribrag, Vincent
    Molin, Daniel
    Vassilakopoulos, Theodoros P.
    Tomita, Akihiro
    von Tresckow, Bastian
    Shipp, Margaret A.
    Lin, Jianxin
    Kim, Eunhee
    Nahar, Akash
    Balakumaran, Arun
    Moskowitz, Craig H.
    [J]. BLOOD, 2019, 134 (14) : 1144 - 1153
  • [6] Kuruvilla John, 2021, Lancet Oncol, V22, P512, DOI 10.1016/S1470-2045(21)00005-X
  • [7] Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
    LaCasce, Ann S.
    Bociek, R. Gregory
    Sawas, Ahmed
    Caimi, Paolo
    Agura, Edward
    Matous, Jeffrey
    Ansell, Stephen M.
    Crosswell, Howland E.
    Islas-Ohlmayer, Miguel
    Behler, Caroline
    Cheung, Eric
    Forero-Torres, Andres
    Vose, Julie
    O'Connor, Owen A.
    Josephson, Neil
    Wang, Yinghui
    Advani, Ranjana
    [J]. BLOOD, 2018, 132 (01) : 40 - 48
  • [8] Lynch RC, 2021, LANCET HAEMATOL, V8, pE562, DOI 10.1016/S2352-3026(21)00170-8
  • [9] Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
    Moskowitz, Alison J.
    Shah, Gunjan
    Schoeder, Heiko
    Ganesan, Nivetha
    Drill, Esther
    Hancock, Helen
    Davey, Theresa
    Perez, Leslie
    Ryu, Sunyoung
    Sohail, Samia
    Santarosa, Alayna
    Galasso, Natasha
    Neuman, Rachel
    Liotta, Brielle
    Blouin, William
    Kumar, Anita
    Lahoud, Oscar
    Batlevi, Connie L.
    Hamlin, Paul
    Straus, David J.
    Rodriguez-Rivera, Ildefonso
    Owens, Colette
    Caron, Philip
    Intlekofer, Andrew M.
    Hamilton, Audrey
    Horwitz, Steven M.
    Falchi, Lorenzo
    Joffe, Erel
    Johnson, William
    Lee, Christina
    Palomba, M. Lia
    Noy, Ariela
    Matasar, Matthew J.
    Pongas, Georgios
    Salles, Gilles
    Vardhana, Santosha
    Sanin, Beatriz Wills
    von Keudell, Gottfried
    Yahalom, Joachim
    Dogan, Ahmet
    Zelenetz, Andrew D.
    Moskowitz, Craig H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28) : 3109 - +
  • [10] Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
    Moskowitz, Craig H.
    Nademanee, Auayporn
    Masszi, Tamas
    Agura, Edward
    Holowiecki, Jerzy
    Abidi, Muneer H.
    Chen, Andy I.
    Stiff, Patrick
    Gianni, Alessandro M.
    Carella, Angelo
    Osmanov, Dzhelil
    Bachanova, Veronika
    Sweetenham, John
    Sureda, Anna
    Huebner, Dirk
    Sievers, Eric L.
    Chi, Andy
    Larsen, Emily K.
    Hunder, Naomi N.
    Walewski, Jan
    [J]. LANCET, 2015, 385 (9980) : 1853 - 1862
12